Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea
Advances in Therapy · 2024
DOI: 10.1007/s12325-024-02832-x ↗Kurz gefasst
Fachartikel in der Zeitschrift Advances in Therapy, 2024. Verfasst von Brian E Lacy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Mayo Clinic, Jacksonville, FL, USA. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Rifaximin, Diarrhea, Gastrointestinal Agents. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Analysis Group.
Abstract (Originalsprache)
INTRODUCTION: Objective assessment of treatment effectiveness using real-world claims data is challenging. This study assessed treatment-free intervals (TFI) as a proxy for treatment effectiveness, and all-cause healthcare costs among adult patients with irritable bowel syndrome with diarrhea (IBS-D) treated with rifaximin or eluxadoline in the USA. METHODS: Adult patients (18-64 years) with IBS-D and ≥ 1 rifaximin or eluxadoline prescription were identified in the IQVIA PharMetrics® Plus database (10/01/2015-12/31/2021) and classified into two mutually exclusive cohorts (i.e., rifaximin and eluxadoline). Index date was the date of rifaximin or eluxadoline initiation. Entropy-balanced baseline characteristics, TFI (periods of ≥ 30 consecutive days without IBS-D treatment), and healthcare costs were reported. Healthcare costs were compared between cohorts using mean cost differences. RESULTS: There were 7094 and 2161 patients in the rifaximin and eluxadoline cohorts, respectively. After balancing, baseline characteristics (mean age 44.1 years; female 72.4%) were similar between cohorts. A higher proportion of patients treated with rifaximin achieved a TFI of ≥ 30 days (76.2% vs. 66.7%), ≥ 60 days (67.0% vs. 47.0%), ≥ 90 days (61.0% vs. 38.7%), ≥ 180 days (51.7% vs. 31.0%), and ≥ 240 days (47.7% vs. 27.9%) compared to eluxadoline. Among patients with a TFI ≥ 30 days, mean TFI durations were 8.3 and 6.0 months for the rifaximin and eluxadoline cohorts. Mean all-cause healthcare costs were lower for rifaximin vs. eluxadoline ($18,316 vs. $23,437; p = 0.008), primarily driven by pharmacy costs ($7348 vs. $10,250; p < 0.001). In a simulated health plan of one million commercially insured lives, initiating 50% of patients on rifaximin instead of eluxadoline resulted in total cost savings of $2.1 million per year or $0.18 per-member-per-month. CONCLUSIONS: This real-world study suggests that TFI is a meaningful surrogate measure of treatment effectiveness in IBS-D. Patients treated with rifaximin had longer treatment-free periods and lower healthcare costs than patients treated with eluxadoline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, Mayo Clinic, Jacksonville, FL, USA.
- Analysis Group, Inc., 1190 Avenue Des Canadiens-de-Montréal, Suite 1500, Montréal, QC, H3B 0G7, Canada.
- Salix Pharmaceuticals, Bridgewater Township, NJ, USA.
- Analysis Group, Inc., 1190 Avenue Des Canadiens-de-Montréal, Suite 1500, Montréal, QC, H3B 0G7, Canada. Rebecca.Bungay@analysisgroup.com.
- Bausch Health, Bridgewater Township, NJ, USA.
- BioNTech US Inc., 40 Erie St, Cambridge, MA, 02139, USA.
ORCID-Profile: Rebecca Bungay
Förderung
- Analysis Group
Zitieren
APA
Lacy, B. E., Gagnon-Sanschagrin, P., Heimanson, Z., Bungay, R., Bellefleur, R., Guérin, A., Bumpass, B., Borroto, D., Joseph, G., & Dashputre, A. A. (2024). Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea. Advances in Therapy. https://doi.org/10.1007/s12325-024-02832-x
Vancouver
Lacy BE, Gagnon-Sanschagrin P, Heimanson Z, Bungay R, Bellefleur R, Guérin A, et al. Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea. Advances in Therapy. 2024. doi:10.1007/s12325-024-02832-x
BibTeX
@article{Lacy2024,
author = {Lacy, Brian E and Gagnon-Sanschagrin, Patrick and Heimanson, Zeev and Bungay, Rebecca and Bellefleur, Remi and Guérin, Annie and Bumpass, Brock and Borroto, Danellys and Joseph, George and Dashputre, Ankur A},
title = {Treatment-Free Interval: A Novel Approach to Assessing Real-World Treatment Effectiveness and Economic Impact Among Patients with Irritable Bowel Syndrome with Diarrhea},
journal = {Advances in Therapy},
year = {2024},
doi = {10.1007/s12325-024-02832-x}
}
EUVIMED